This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
J&J's $8B Jury Award in Risperdal Case Cut to $6.8M by Judge
by Zacks Equity Research
A Philadelphia judge slashes J&J's (JNJ) punitive damages in a lawsuit, which claims that the company did not warm men that they could grow breasts by using its antipsychotic drug, Risperdal.
The Zacks Analyst Blog Highlights: AAPL, JNJ, PG and AXP
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AAPL, JNJ, PG and AXP
The Zacks Analyst Blog Highlights: JPM, JNJ, CVX and PG
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPM, JNJ, CVX and PG
The Zacks Analyst Blog Highlights: JNJ, BHP, MCO, NVDA and DAL
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JNJ, BHP, MCO, NVDA and DAL
Is Johnson & Johnson (JNJ) A Good Pick for Value Investors?
by Zacks Equity Research
Is Johnson & Johnson (JNJ) a great pick from the value investor's perspective right now? Read on to know more.
Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat?
by Zacks Equity Research
J&J's (JNJ) cancer drugs are expected to have contributed significantly to fourth-quarter 2019 earnings. Generic/biosimilar headwinds are expected to have hurt Pharma unit's sales.
Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates
by Kinjel Shah
Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.
Q4 Earnings Season Showing Revenue Momentum
by Sheraz Mian
We are starting to see clear signs of momentum on the revenue side in the Q4 results that we have seen already. This could very well be a head fake and a reflection of our desire to look for 'green shoots' in the earnings landscape...
Will Dow ETFs Continue to Surge as Q4 Earnings Unfold?
by Sweta Killa
With most blue-chip companies' earnings scheduled over the coming weeks and sentiments being mixed, investors should closely monitor the movement of the Dow ETF.
4 Blue-Chip Stocks to Win Big on Phase-One Trade Deal
by Nilanjan Banerjee
Wall Street rallied following the first phase of the U.S.-China trade pact, with Dow Jones Industrial Average and S&P 500 closing at record highs.
J&J Seeks Label Expansion for Spravato Nasal Spray in EU
by Zacks Equity Research
J&J (JNJ) seeks label expansion for its new nasal spray, Spravato (esketamine), for an expanded patient population in Europe.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
4 Must-Buy Dow Stocks Ahead of Earnings Reports This Month
by Nalak Das
The last three months of the year were quite promising for the Dow as the U.S.-China trade war finally seemed to ease.
Q4 Earnings Scorecard & Today's Top Stock Research Reports
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), BHP Group (BHP) and Moody's (MCO).
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $147.01, moving +0.33% from the previous trading session.
Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Large-Cap Dividend Stocks to Buy Now for Your 2020 Portfolio
by Benjamin Rains
Despite all the positivity, investors should think about adding a few large-cap stocks that pay a solid dividend to help anchor their portfolios in 2020...
Healthpeak (PEAK) Leases Phase II at The Shore at Sierra Point
by Zacks Equity Research
Healthpeak's (PEAK) lease with Janssen BioPharma at The Shore at Sierra Point reflects solid demand for space at this centrally-located property in the large life-science cluster.
Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again
by Zacks Equity Research
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Glaxo Files Marketing Application for Fostemsavir in Europe
by Zacks Equity Research
Glaxo (GSK) submits an MAA in Europe for its investigational candidate fostemsavir, which is being developed for treating HIV-1 infection in heavily pre-treated adult HIV patients.
The Zacks Analyst Blog Highlights: JPMorgan Chase, Johnson & Johnson, American Express Company, NIKE and Apple
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan Chase, Johnson & Johnson, American Express Company, NIKE and Apple
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Dow Heads Toward 29,000: Grab 5 Blue-Chip Stocks Now
by Tirthankar Chakraborty
There has been a particularly sharp run-up in blue-chip stocks. These companies are slated to see gains as they have strong balance sheet and solid cash flow.
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $145.39, marking a +0.3% move from the previous day.
Pacira's (PCRX) Exparel Meets Key Goals in C-Section Study
by Zacks Equity Research
Pacira's (PCRX) phase IV CHOICE study on its lead drug Exparel in patients undergoing Cesarean section attains the primary as well as key secondary endpoints.